OBJECTIVES: The optimal prosthesis option for aortic valve replacement in adult patients <60 years of age with severe aortic stenosis (AS) remains controversial. The objective was to determine the long-term outcomes of the Ross procedure in this population.
INTRODUCTION
The Ross procedure offers numerous advantages, such as normal aortic valve haemodynamics, absence of late calcification and stenotic degeneration of the autograft, low endocarditis risk, low thrombogenicity and the absence of a need for long-term anticoagulation [1] [2] [3] [4] [5] . It was also demonstrated to provide a survival comparable with that of the general population, allowing for unrestricted daily activities and an excellent quality of life [1] [2] [3] [4] [5] . This surgical option for aortic valve replacement (AVR) is clearly the gold standard option in the paediatric population but remains controversial in adult patients because of the risk of reoperation for both the aortic autograft and pulmonary homograft, along with the technically demanding nature of this operation. The risk of reoperation after a Ross procedure was proved to be greater in patients in whom the initial predominant pathology was aortic regurgitation (AR) compared with those with predominant aortic stenosis (AS) [1, 4, 6] . Nevertheless, there is a need to evaluate the long-term outcomes of this procedure in the specific subgroup of adult patients with predominant AS in order to identify which patient characteristics, if any, make the Ross procedure most beneficial in patients undergoing AVR compared with other prosthetic options. The objective of this study was thus to determine the long-term outcomes of the Ross procedure in adult patients <60 years of age with predominant AS in a large single-centre study. This information could serve as a basis for comparing the outcomes of the Ross procedure in young and middle-aged adults with that of other surgical options for the treatment of AS.
MATERIALS AND METHODS

Patient characteristics
Between 1990 and 2013, 276 adult patients between 18 and 60 years of age (mean: 40.3 ± 10.6 years) underwent an elective Ross procedure at the Quebec Heart and Lung University Institute, Quebec City, Canada. Among these, 221 patients had predominant severe AS defined as a mean preoperative trans-valvular gradient on transthoracic echocardiography of >40 mmHg, with or without trivial to moderate AR. These patients formed our study group. Patients with pure or predominant severe AR were excluded from the study group as they represent a different group with their own natural evolution [5] and outcomes after the Ross procedure [1, 4, 6] . During the time period of this study, 6724 elective AVRs (excluding the Ross procedure) with or without coronary artery bypass graft (CABG) surgery were performed in our institution. The choice of prosthetic aortic valve type was based on surgeon preference and expertise. Preoperative coronary angiography was routinely performed in all patients aged 40 years and above and in patients undergoing redo sternotomy. In patients aged <40 years, coronary angiography was selectively performed only in the presence of a risk factor for coronary artery disease such as family history, diabetes, hypertension, smoking and hyperlipidaemia. This study was approved by the institutional review board and all patients provided their informed consent.
Demographic, preoperative, postoperative and longitudinal clinical and echocardiographic data were collected prospectively. The clinical and operative characteristics of the patient population are depicted in Table 1 . The median and mean ages of our patients at surgery were 43 (18-59 years) and 41.5 ± 10.4 years, respectively. There were 169 (76.5%) patients with bicuspid aortic valve and 33 (14.9%) redo operations including previous aortic valve repair (n = 6) and replacement (n = 9) for severe AS. The AS was associated with mild or moderate AR in 116 (52.5%) and 41 (18.6%) of cases, respectively. All indications for the primary operation and for all reoperations were in accordance with the 2008 American Heart Association guidelines [7] . The Ross procedure was performed either by aortic root replacement (n = 190; 86%) or the subcoronary technique (n = 31; 14%). The choice of the surgical technique was at the discretion of the surgeon. In the subcoronary technique, care was taken not to change the level and site of fixation of the commissure of the pulmonary autograft to accommodate the coronary artery orifice. Preoperative patient characteristics according to the surgical technique used are compared in Table 2 .
Follow-up
All of the patients were followed annually in our dedicated valve clinic. Clinical and echocardiographic follow-up were complete in all of the patients. They had a prospective yearly follow-up including a clinical assessment as well as 2D echocardiography with colour Doppler evaluation at our institution. Any valve-related morbidity was in accordance with the American Association for Thoracic Surgery and the Society of Thoracic Surgeons Committee guidelines for standardizing prosthetic heart valve morbidity. The end of the follow-up period was January 2013.
Statistical analysis
Results are expressed as the mean ± standard deviation or the median (inter-quartile or minimum to maximum range, as indicated) for continuous variables, and percentages for categorical variables. Patients were censored at the time of last contact. Continuous and dichotomous variables were analysed using Student's t-test or χ 2 test, respectively. All of the parameters were initially analysed using univariate Cox regression models to estimate the hazard ratio of each variable with respect to longitudinal outcomes. The endpoints studied at the most recent follow-up were early and late mortality, autograft valve insufficiency (defined as a regurgitation grade at least moderate) and Ross reoperations on the autograft or homograft. A Ross-related reoperation was defined as any surgical procedure performed after the initial Ross procedure on the autograft or homograft. No catheter-based reintervention was required during the entire follow-up for the pulmonary homograft. Cardiac non-valvular, as well as valvular but non-Ross-related, were not considered as Ross-related reoperations. Time-related analysis was performed by the Kaplan-Meier method and the mean and median follow-up times were calculated using the reverse KaplanMeier technique. Long-term survival, freedom from autograft valve insufficiency and freedom from Ross-related reoperations on the autograft or homograft were assessed. The univariate risk analysis of time-related events was achieved with the log-rank test and the univariate Cox model. Statistical significance was present when twotailed P < 0.05. Analyses were performed using the statistical software version package of SAS 9.2 (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Early mortality and morbidity
The in-hospital mortality rate was 0.9% (n = 2). The cause of death in these 2 patients (aged 38 and 46 years) was refractory postoperative cardiogenic shock and multiorgan failure; both were implanted with bi-ventricular assist devices. In both patients, autopsy confirmed the absence of coronary artery ischaemic events. The most frequent early complications were de novo atrial fibrillation (n = 33; 14.9%) and reoperation for bleeding (n = 13; 5.9%). Postoperative complications and outcomes according to the surgical technique used are compared in Table 2 . Postoperative complications in all patients are shown in Table 3 . At discharge, the average maximum trans-valvular aortic gradient by echocardiography was 9.8 ± 6.7 mmHg. The mean left ventricular ejection fraction was 61.1 ± 9.7%. One patient had a moderate central AR at discharge. Data regarding aortic annulus, sinus of Valsalva, and ascending aortic diameters at discharge and at last follow-up are depicted in Table 3 .
Long-term outcomes
The median and mean follow-up were 11.4 years (range: 0.5-20.1 years) and 10.1 ± 5.9 years. The follow-up was complete in all patients.
Reoperation. Twenty-three patients (10.5%) had a moderate or moderate-to-severe autograft valve insufficiency at the last follow-up; 15 required an autograft reoperation. Twenty-one patients (9.5%) required a reoperation either on the autograft (n = 9; 4.1%), the homograft (n = 6; 2.7%) or both (n = 6; 2.7%) during the entire time of follow-up. No catheter-based reintervention was required during the same time interval. Characteristics, indications, surgical procedures and outcomes of the patients with autograft and homograft reintervention are presented in Tables 4 and 5 , respectively. Four patients had a third operation: 2 patients, who had undergone a valve-sparing procedure at reoperation, required another autograft reoperation (one for structural valve dysfunction 1 year after the first reoperation and the other one, for endocarditis 6 months after the first reoperation); 2 patients had two pulmonary valve replacements. Three of them are alive and in NYHA functional status Class 1 in their last follow-up; 1 died during the postoperative course from a cardiac failure. At the last follow-up, the average mean aortic trans-valvular gradients at 10 and 15 years were 6.0 ± 5.3 and 7.1 ± 5.3, respectively. Actuarial freedom from autograft valve insufficiency, freedom from overall Ross-related reoperation, and freedom from reoperation on the autograft and homograft are displayed in Fig. 1 . The rate of freedom from moderate or severe autograft valve insufficiency was 94.1% (95% confidence interval (CI) 0.92-0.96) and 85.6% (95% CI 0.80-0.92) at 10 and 15 years, respectively. In univariate risk analysis, no factors were identified that were significantly associated with an increased risk of autograft valve insufficiency (defined as a neoaortic valve regurgitation grade at least moderate), requiring reoperation (Table 6 ). Associated preoperative mild or moderate AR (P = 1.0) and the surgical technique of the Ross procedure (subcoronary vs root replacement, P = 0.24) were not significantly associated with an increased risk of autograft reoperation.
Survival. During the entire period of follow-up, 15 patients (6.8%) died. Among them, there were 6 (2.7%) cardiac-related late mortalities due to myocardial infarction (n = 3) and sudden death (n = 3). There were also nine non-cardiac-related deaths (4.1%). The overall actuarial survival rate at 10 and 15 years following surgery was 92.0% (95% CI 0.87-0.96) and 90.5% (95% CI 0.88-0.94), respectively (Fig. 2 ). There was no major cerebrovascular accident during the follow-up. Surgical technique (subcoronary vs root replacement) was not significantly associated with late survival. 
DISCUSSION
One-fifth of the 200 000 patients worldwide who undergo an AVR each year are young or middle-aged adults (18-60 years of age) [8] . Choosing the optimal aortic valve prosthesis for this specific subgroup of patients still presents a challenge, since all the available options (mechanical valve, bioprosthetic (stented and stentless) valves, homografts and Ross procedure) bring numerous advantages and disadvantages that the patient and physician have to weigh carefully before making a decision. The Ross procedure, which accounts for only 2-3% of AVR procedures worldwide along with homografts [9] , is controversial in adult patients, in contrast to the paediatric population, where the autograft growth potential represents an undeniable advantage over all other therapeutic alternatives.
The present study shows that the Ross procedure could potentially provide a very good long-term option in a subgroup of young and middle-aged patients with predominant AS who seek a durable operation without anticoagulation. These results can help enlighten patient-physician discussions before aortic valve interventions in young adults. The present study analysed a variety of clinically relevant outcomes after the Ross procedure in a large, single-centre cohort prospectively followed for up to 20 years with the median follow-up >11 years, which constitutes one of the longest durations of follow-up to our knowledge.
Only patients with predominant AS were included in this series for the following reasons: (i) AS and AR are two different clinical entities in terms of patient characteristics, natural history and late outcomes [6] ; (ii) patients with AR, in whom baseline annular dilatation is expected to be more frequent, have been demonstrated as being more prone to autograft failure and reoperation [1, 4, 6], making the Ross procedure less suitable for this indication; (iii) excluding patients with AR in this series allowed us to increase the homogeneity of the study patients and allowed us to make meaningful statements about long-term outcomes with greater certainty and generalizability; and (iv) to serve as a basis for comparison with the other currently available surgical options for AS.
In young and middle-aged adult patients with AS, mechanical valves are currently the most often used valve prostheses [10] , despite the lifetime risk of major haemorrhagic and thromboembolic events evaluated at 2-4% per year of life [11] . This risk means that most patients who undergo an AVR using a mechanical valve in their 30-40 s will suffer a major haemorrhagic or thromboembolic event in their 60-70 s. The Ross procedure largely avoids this major drawback [4] . In the present study, there were no cerebrovascular accidents related to ischaemic or haemorrhagic causes during the entire follow-up. The risk of prosthesis dysfunction requiring reoperation after the implantation of a mechanical valve in the aortic position seems to be frequently underestimated. Despite an excellent mechanical durability, mechanical valves in young and middle-aged patients can be complicated by pannus formation, valve thrombosis, endocarditis or paravalvular leaks, and require a reoperation in 5 and 10% of cases at 10 and 15 years, respectively [12, 13] . The published risk of aortic valve reoperation after mechanical valve implantation appears to be higher than the risk of autograft reoperation observed in our present Ross series (2.4 and 8.5% at 10 and 15 years), although this was not a comparative study and our data must be interpreted accordingly.
Aortic homografts represent another alternative, although less frequent, for the treatment of AS in this population. But this surgical option does not offer a survival benefit and might be less [14] showed that almost 50% of patients <50 years of age who underwent the implantation of an aortic homograft required a reoperation by 12 years. Again, the outcomes of the Ross procedure in the present study compare favourably with the data of a randomized trial comparing the Ross procedure with aortic homografts by El-Hamamsy et al. [15] , which showed that the rate of freedom from reoperation of the aortic root at 10 years was 99% for the Ross procedure and 82% for homografts. Bioprosthetic valves are increasingly used to treat AS in young and middle-aged adults [16] , mainly for four reasons: (i) the fact that the durability of mechanical valves is not associated with an increased long-term survival seems to be largely recognized by medical and surgical teams [17] ; (ii) the acceptance by many patients of the late risk of reoperation for a bioprosthetic valve in light of the linear lifelong risk of anticoagulant therapy required for mechanical valves [18] ; (iii) technological and biological advances (anticalcification techniques, low or zero-pressure fixation, etc.) leading to the development of third-generation bioprostheses with purported longer durability; and finally (iv) the possibility of a less-invasive reintervention provided by transcatheter valve-in-valve implantation make bioprostheses alluring options for younger patients; however, robust long-term data for valve-in-valve procedures in biological stented or stentless valves are currently lacking. Nevertheless, one-third of middle-aged patients implanted with a second-generation bioprosthesis present with a structural valve degeneration by 12-15 years [17] .
The present study shows that the Ross procedure is associated with excellent results when performed in young and middle-aged patients with predominant AS. Our series reports an actuarial rate of moderate or severe autograft valve insufficiency of 6 and 14% at 10 and 15 years, respectively, and autograft reoperation of 2 and 8% at 10 and 15 years, respectively. The overall rates of Ross-related reoperation are 5.3 and 12.3% at 10 and 15 years. These excellent results of the Ross procedure in this selected subgroup of patients are concordant with the data published by Charitos et al. [18] , who reported a 95% freedom from autograft reoperation (using the reinforced root technique) and 98% freedom from homograft reoperation at 10 years. Long-term results of 203 young and middle-aged patients with >10 years of follow-up after the original subcoronary Ross operation showed similar results with a rate of freedom from autograft or allograft reoperation of 92.2% at 10 years and 87.1% at 15 years [2] . Although no randomized trials directly comparing the Ross procedure to bioprostheses have been performed, data in the recent literature show that the outcomes of the Ross procedure in these middle-aged patients with predominant AS compare favourably to those of bioprosthetic valves in mid-and long-term follow-up [2, 4, 10, [16] [17] [18] [19] . A review by Carpentier and coworkers [10] reports that the rate of reoperation after the Ross procedure in middle-aged patients with AS is probably less than that associated with bioprosthetic valve implantation in this specific population, even if randomized comparative trials are still lacking. McClure et al. [20] report an 87.8% freedom from reoperation for structural valve degeneration at 10 years in a large series of patients <65 years of age receiving the Carpentier-Edwards Perimount bioprosthesis. Similar outcomes were reported in other series of middle-aged patients receiving the same or other stented bioprostheses. Kouchoukos [19] revealed that unpublished data from Edwards Lifesciences (Edwards Lifesciences Corp., Irvine, CA, USA) for the Perimount bioprosthesis show that the rate of freedom from reoperation is 93 and 74% among patients aged <45 years at 10 and 15 years, respectively. The durability of stentless prostheses may be even lower; our group has previously reported a 62.6% freedom from reoperation for structural valve degeneration at 15 years in a series of patients <60 years of age with a stentless aortic bioprosthesis [21] . Critical analyses of outcomes following the Ross procedure have identified several other important risk factors associated with an increased need for reoperation. These include preoperative aortic annular dilatation (>27 mm) and the surgical implantation technique [2, 5, 6, 22] . A lower frequency of preoperative annular dilatation in this cohort may explain the improved late risk of reoperation in the subgroup of patients with severe AS that was observed in our study. However, the systematic use of reinforcement techniques of the autograft especially in patients with a dilated root has been suggested by some authors [22, 23] to decrease the rate of reoperation. We were not also able to show any differences in terms of mortality, morbidity, late autograft valve regurgitation and reoperation between the subcoronaryand the root replacement technique. Similar findings have been published by another large series [6] .
Finally, advancements in transcatheter techniques of aortic and pulmonary valve replacement [24] may also make the Ross procedure more suitable for selected patients by decreasing the invasiveness of reinterventions for autograft or homograft failure, although this benefit remains hypothetical.
Study limitations
This is a descriptive observational study without a comparator group and lack of random treatment allocation limits the conclusions we can draw from such data. However, the acquisition of community-wide clinical as well as echocardiographic data by our outpatient dedicated valve clinic out to >20 years following the Ross procedure and a median follow-up >11 years in a homogeneous group of adult patients is a definite strength of our study.
Multivariate analysis was not possible due to the very few number (<20) of adverse events [25] . Also, the limited number of patients remaining at risk after 15 years of follow-up makes it difficult to draw any meaningful conclusions beyond those time points.
Conclusion
Compared with the therapeutic surgical options available in the recent literature to treat AS in young and middle-aged adult patients, the Ross procedure provides an excellent long-term option for these patients who seek a durable operation without anticoagulation.
APPENDIX. CONFERENCE DISCUSSION
Dr H. Schäfers (Homburg/Saar, Germany): You have shown again that for aortic stenosis, at least for the first 15 years, the Ross operation seems to be a very good option. More than 90% freedom from reintervention at 15 years is excellent.
However, having said that, there was a worrisome drop in your freedom from reoperation curve from 15 to 20 years. So at 20 years we're only in the 70% range, which makes one wonder is it really the 'once in a lifetime' operation that we tend to believe, or is it simply a biological replacement that has a better durability than a bioprosthesis?
I have three questions that I would like you to address: Specifically for this analysis you excluded AR, but it is just the subgroup with AR that has been the subject of controversial discussion. Even though it's not the content of the paper, maybe you could comment on the durability of the Ross, because you have 50 patients with AR.
Second, you used root replacement mainly. Do you have comments about the recent trend (and you also saw some autograft dilatation over the course of time) of creating a supported root replacement, whether it is with remnants of aortic wall, as I use myself, or other surgeons use some prosthetic material around the autograft to prevent dilatation.
And finally, given the drop in freedom from reintervention at beyond 15 years, you have a wide age span, for the 50-year-old patient maybe the option of two biological valves, one at the age of 50, reoperation at 63, would be an alternative to the Ross operation, and then leaving the right ventricle untouched.
Dr Kalfa: The first question was regarding AR. We purposely excluded patients with AR. We wanted to evaluate the outcomes of the Ross procedure in this very specific population of patients with aortic stenosis, and for the results that you already know.
Dr Schäfers: Maybe you don't have the exact numbers, but you see the patients when they come back for reoperations. Have you seen more autograft dilatation in the AR group?
Dr Kalfa: The answer is clearly no. We had actually, roughly, the same results in terms of autograft dilation, homograft reoperation, and autograft reoperation among the patients with aortic stenosis and aortic regurgitation. However, the number of patients with severe AR was limited.
The second question was regarding the reinforcement techniques. Yes, we have experience with that, and I personally think that they could be very useful. We have some experience with complete inclusion of the autograft in a Dacron tube, with good outcomes in terms of autograft dilation.
And the third question was? Dr Schäfers: What about the 51-year-old, would you recommend Ross as the perfect solution or the option of two biological prostheses?
Dr Kalfa: That's an excellent question, and I don't really have the answer. The main positive point in favour of the Ross procedure is I think that a 50 year-old patient with severe aortic stenosis without root dilatation and low perioperative risk factors could have potentially a life-long benefit from a Ross procedure in experienced hands. In case of eventual late failure of both auto and homograft, a percutaneous valve implantation might be a good answer for this type of patient. On the other hand, you are completely right regarding all the figures that we presented displaying a drop in the freedom from reoperation curve from 15-20 years. So maybe in a 50-year-old patient we could be more moderate regarding the place of the Ross procedure.
Dr M. Ezzat (Cairo, Egypt): I worked in the early '90s in a good centre in France and I visited many centres in the United States. The option at that time, this is the trend of the development of the Ross procedure, the option for middle-aged persons was to choose between a homograft aorta and a mechanical valve. The Ross procedure was not at that time, in the early and mid '90s, regarded as an option for middle-aged persons.
Dr J. Takkenberg (Rotterdam, Netherlands): I have a question. Your study suggests that over the time period of your study you operated on approximately 10 to 12 patients each year, you did a Ross procedure on them. I guess you had more patients within that age group, and I wonder how do you inform your patients? Do you always offer the Ross procedure? And what do you think is most appropriate?
Dr Kalfa: The patients are generally given all the pertinent information regarding operation including all the possible options of AVR with advantages and disadvantages of each option. The final decision also depends on the comorbidities of the patient and indications or contraindications to anticoagulant therapy. Besides the conviction of the surgeon on the Ross procedure, the final decision is based on the discussion between the patient and the surgeon. We don't have any specific protocol to decide the type of valve which will be implanted. It will be based on a case-by-case discussion between the surgeon and the patient.
Dr Takkenberg: And do you tell them about the operative risk? The STS database suggests that it's higher compared to conventional aortic valve replacements. I disagree with that, but I'm not sure; what do you tell your patients?
Dr Kalfa: Between what and what? Dr Takkenberg: The operative mortality between the Ross procedure and standard aortic valve replacement, is there a difference, do you tell your patients?
Dr Kalfa: I believe like you it doesn't seem to me any difference. Dr Takkenberg: No, in your hands it does not. But I was wondering, because right now the STS database suggests that we should abandon the Ross procedure because it carries an increased operative risk. But I guess in a centre of excellence like yoursDr Kalfa: We clearly don't think that the Ross procedure should be abandoned for sure.
Dr Takkenberg: That's reassuring to learn.
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